THE COUNCIL FOR TOBACCO RESEARCH–U.S.A., INC.

CONFIDENTIAL REPORT

SCIENTIFIC ADVISORY BOARD MEETING

SANTA BARBARA, CALIFORNIA

MARCH 26-27-28, 1975

Attendance

| | |
|---|---|
| Dr. Sheldon C. Sommers, Chairman | |
| Dr. Richard J. Bing (3/26-27) | |
| Dr. Joseph D. Feldman | |
| Dr. William U. Gardner | Scientific Director, CTR |
| Dr. Robert J. Huebner | |
| Dr. Leon O. Jacobson | |
| Dr. Averill A. Liebow | |
| Dr. Henry T. Lynch | |
| Dr. John P. Wyatt | |
| Dr. Helmut R. R. Wakeham | Chairman, ITC |
| Joseph L. Goldstein, M.D. (3/26) | University of Texas, Southwestern Med. Sch. |
| Jay A. Levy, M.D. (3/28) | University of California, San Francisco |
| George J. Popjak, M.D. (3/26) | University of California, Los Angeles |
| J. S. M. Sarma, Ph.D. (3/26) | Huntington Memorial Hospital |
| Mr. H. H. Ramm | President, CTR |
| Mr. W. T. Hoyt | Executive Vice President, CTR |
| Dr. Robert C. Hockett | Research Director, CTR |
| Dr. John H. Kreisher | Associate Research Director, CTR |
| Dr. David Stone | Associate Research Director, CTR |
| Dr. Vincent F. Lisanti | Research Associate, CTR |
| Mr. Leonard S. Zahn | Leonard Zahn and Associates, Inc. |

1. The report of the meeting of the Scientific Advisory Board, held on October 30-31, November 1, 1974 was approved.

2. The report of the meeting of the Executive Committee of the SAB, held on December 13, 1974, was approved.

1003540487

Source: https://www.industrydocuments.ucsf.edu/docs/ykpl0000

3. The following administrative actions were approved as attached:

Authorizations

Subsequent to the October 1974 Advisory Board meeting, of the new applications recommended for approval, the Scientific Director determined that the following should be funded in the respective amounts indicated:

983 Leo G. Abood, Ph.D. $16,771.00 for ten months or at a rate of $20,125.00 per year.

1003 Edward L. Klaiber, M.D. $20,332.00

Subsequent to the October 1974 SAB meeting, of the renewal applications recommended for approval, the Scientific Director determined that the following should be funded in the amount indicated:

24PS4 Paul S. Larson, Ph.D. $66,753.00

Subsequent to the October 1974 SAB meeting the Scientific Director determined that the following proposal for contract renewal should not be funded:

2-G Microbiological Associates Inc. $181,560.00 (Animal carcinogenic models.)

However, in order to permit completion of some phases of the contract not completed under Contract 2-F, the Scientific Director determined that the following supplement should be funded for six months in the amount indicated:

14-AS Microbiological Associates Inc. $55,000.00

Subsequent to the October 1974 SAB meeting, of the new applications that were deferred, the Scientific Director, with the approval of the Executive Committee of the SAB, determined that the following should be funded in the amount indicated:

787-BS Gary D. Friedman, M.D. $24,860.00 for three months.

Actions

Contract

9-DS University of San Francisco. At the Executive Committee meeting of the SAB held on December 13, 1974, the supplement authorized was incorrectly noted in the minutes as $20,117.00. The final amount authorized is $20,101.02.

Grants

572-CS Jay A. Levy, M.D. $10,000.00 On page 10 of the minutes of October 30-31, November 1, 1974, the above authorization should have indicated grant #572-CS instead of #1011.

766-A Richard A. Lerner, M.D. An unexpended balance of $3.02 was returned and deposited.

1003540488

Source: https://www.industrydocuments.ucsf.edu/docs/ykpl0000

776-AM Elliot S. Vesell, M.D. Authorization was given to rebudget $3,210.00 from Volunteer Fees to Salaries.

814R2 Una S. Ryan, Ph.D. Permission was granted to carry forward an unspent balance of $6,310.00 to grant #814-A toward the purchase of a new LKB Ultratome III.

906S Robert E. Brooks, Ph.D. $621.45 This supplement was approved to cover a deficit incurred in the first year of a proposed three-year project which was terminated at the end of the first year.

923 Guenther Boden, M.D. Permission was granted to carry forward unexpended funds of $12,053.09 on hand at December 31, 1974 to grant #923R1, the second year of the project.

929 Edward Leete, Ph.D. Permission was granted to carry forward an unspent balance of $6,978.84 beyond the expiration date of December 31, 1974 to December 31, 1975, with the proviso that a final financial report be received as soon as possible.

1013 Malcolm C. Pike, Ph.D. The final award was approved at $68,581.00 instead of $63,899.00, reflecting a 12% fringe benefit figure on salaries and wages which had been overlooked.

4. The following renewal applications were recommended for approval subject to the determination by the Scientific Director as to priority and the amount to be funded:

455-BR2 Charles L. Rose, Ph.D. (formerly Bell) $64,000.00

467-CR1 Thomas C. Westfall, Ph.D. $30,597.00

519-CR1 Louis A. Soloff, M.D. $80,329.00

870R2 H. J. Eysenck, Ph.D. £9,315.

884MR1 Albert Castro, Ph.D. $40,120.00

901MR1 George Weinbaum, Ph.D. $40,538.00

918R1 H. Fred Downey, Ph.D. $15,784.00

922MR1 Joseph C. Arcos, D.Sc. $67,279.00

933R1 Charles R. Shaw, M.D. $53,353.00

935MR1 William H. Fishman, Ph.D. $51,368.00

939R1 R. G. Mason, M.D. $28,285.00

941R1 Henry T. Lynch, M.D. Part I. $38,908.00
Part II. $36,515.00

949R1 B. V. Rama Sastry, Ph.D. $14,107.00

951R1 Hans Meier, D.V.M. $27,010.00

1003540489

Source: https://www.industrydocuments.ucsf.edu/docs/ykpl0000

961R1 Dov Michaeli, Ph.D. $84,966.00

966R1 Nathan H. Sloane, Ph.D. $11,500.00

973R1 Ronald E. Rasmussen, Ph.D. $51,446.00

974R1 Stephen F. Vatner, M.D. $27,106.00

985R1 Gary Friedman, M.D. $90,340.00

5. Of the new applications deferred at the meeting of the SAB on October 30-31, November 1, 1974, the following were recommended for approval subject to the determination by the Scientific Director as to priority and the amount to be funded:

787-C Gary Friedman, M.D. $111,900.00

1010M Carl G. Becker, M.D. $29,908.00

1011 Jay A. Levy, M.D. $60,245.00

6. Of the applications deferred at the meeting of the SAB on October 30-31, November 1, 1974, the following was rated for disapproval:

966 John A. Terzakis, M.D. $15,180.00

7. The following new applications were recommended for approval subject to the determination by the Scientific Director as to priority and the amount to be funded:

725-D Jack Chalon, M.D. $25,254.00

764-D Charles G. Cochrane, M.D. $25,818.00

766-B Richard A. Lerner, M.D. $79,178.00

862-A James Travis, Ph.D. $45,081.00

864-C Theodore A. Slotkin, Ph.D. $18,359.00

869-A Ronald P. Rubin, Ph.D. $18,975.00

892-A Lars Friberg, M.D. $43,923.00

954-A Allen B. Cohen, M.D., Ph.D. $65,762.00

1012 J. Andrew Mitchell, Ph.D. $6,887.00

1014 G. J. Gleich, M.D. $8,345.00

1015 Alphonse A. Ingenito, Ph.D. $29,910.00

1020 Marc D. Thames, M.D. $12,500.00

1022 John L. Egle, Ph.D. $29,813.00

1023 Patricia I. Bader, M.D. $52,385.00

10035404490

Source: https://www.industrydocuments.ucsf.edu/docs/ykpl0000

1027 William F. Benedict, M.D. $43,513.00

1028 George Wolf, Ph.D. $23,168.00

8. The following new applications were rated for disapproval:

547-E Joseph J. Guarneri, Ph.D. $45,713.00

976M Stephen M. Ayres, M.D. $41,611.00

1016 William Ho, M.A. $55,481.00

1017 Gordon W. Gribble, Ph.D. $21,090.00

1018 William E. Connor, M.D. $37,605.00

1019 Simon H. Wender, Ph.D. $23,449.00

1024 Ronald D. Fletcher, Ph.D. $19,847.00

9. The following new applications were deferred:

310-A Richard J. Bing, M.D. $46,971.00 Staff is to arrange for peer review with final decision to be made by the Executive Committee of the SAB or pro rated for decision at the September SAB meeting.

758-C Hans Meier, D.V.M. $24,973.00 Staff is to arrange for peer review with final decision to be made by the Executive Committee of the SAB or pro rated for decision at the September SAB meeting.

1021 Giles D. Filley, M.D. $43,522.00 For consideration at September meeting.

1025 Charles Mittman, M.D. $7,877.00 For consideration at September meeting.

1026 Ze'ev Trainin, D.V.M. $31,175.00 For consideration at September meeting.

10. The following proposals for contract renewal were recommended for approval subject to the determination by the Scientific Director as to priority and the amount to be funded:

14-B Microbiological Associates Inc. $522,794.00

15-B Union Carbide Corporation $368,300.00

16-B Scripps Clinic and Research Foundation. (Richard A. Lerner, M.D. $65,872

20-A Microbiological Associates Inc. $25,000.00 (Reference cigarette storage.)

22-A Microbiological Associates Inc. $900,000.00

28 Microbiological Associates Inc. $40,685.00 (Kouri collaboration with Jay A. Levy, M.D. [grant 1011].)

10035491

Source: https://www.industrydocuments.ucsf.edu/docs/ykpl0000

11. The next meeting of the Scientific Advisory Board was scheduled for September 10-11-12, 1975.

12. Dr. S. C. Sommers was reelected Chairman of the Scientific Advisory Board for a term of one year.

13. Following a discussion of the advisability of having terms of office for Scientific Advisory Board members, the Scientific Director was asked to collaborate with the Chairman of the Advisory Board in formulating a procedure covering members' tenure on the Board.

14. Subsequent to the meeting, of the renewal applications recommended for approval and referred to in paragraph 4, the Scientific Director determined that the following should be funded in the respective amounts indicated:

| | |
|---|---|
| 455-BR2 | Charles L. Rose, Ph.D. $64,000.00 |
| 467-CR1 | Thomas C. Westfall, Ph.D. $30,597.00 Terminal. |
| 519-CR1 | Louis A. Soloff, M.D. $69,167.00 Terminal. |
| 870R2 | H. J. Eysenck, Ph.D. $22,000.00 Terminal. |
| 884MR1 | Albert Castro, Ph.D. $30,090.00 4/1-12/31/75 |
| 901MR1 | George Weinbaum, Ph.D. $40,538.00 |
| 918R1 | H. Fred Downey, Ph.D. $15,784.00 |
| 922MR1 | Joseph C. Arcos, D.Sc. $56,000.00 No commitment. |
| 933R1 | Charles R. Shaw, M.D. $28,000.00 4/1-12/31/75 |
| 935MR1 | William H. Fishman, Ph.D. $51,368.00 |
| 939R1 | R. G. Mason, M.D. $28,285.00 |
| 941R1 | Henry T. Lynch, M.D. $68,000.00 Includes Parts I and II. |
| 949R1 | B. V. Rama Sastry, Ph.D. $14,107.00 Terminal. |
| 951R1 | Hans Meier, D.V.M. $27,010.00 |
| 961R1 | Dov Michaeli, Ph.D. $74,000.00 |
| 966R1 | Nathan H. Sloane, Ph.D. $11,500.00 |
| 973R1 | Ronald E. Rasmussen, Ph.D. $51,446.00 No commitment. |
| 974R1 | Stephen Vatner, M.D. $27,106.00 |
| 985R1 | Gary Friedman, M.D. $90,340.00 Terminal. |

10035404492

Source: https://www.industrydocuments.ucsf.edu/docs/ykpl0000

15. Subsequent to the meeting, of the new applications recommended for approval and referred to in paragraph 7, the Scientific Director determined that the following should be funded in the respective amounts indicated:

| | | |
|---|---|---|
| 725-D | Jack Chalon, M.D. | $25,254.00 |
| 764-D | Charles G. Cochrane, M.D. | $25,818.00 |
| 766-B | Richard A. Lerner, M.D. | $55,000.00 |
| 862-A | James Travis, Ph.D. | $45,081.00 |
| 892-A | Lars Friberg, M.D. | $43,923.00 |
| 954-A | Allen B. Cohen, M.D., Ph.D. | $58,326.00 |
| 1012 | J. Andrew Mitchell, Ph.D. | $6,887.00 |
| 1014 | G. J. Gleich, M.D. | $8,345.00 |
| 1015 | Alphonse A. Ingenito, Ph.D. | $29,910.00 |
| 1020 | Marc D. Thames, M.D. | $12,500.00 |
| 1027 | William F. Benedict, M.D. | $43,513.00 |
| 1028 | George Wolf, Ph.D. | $23,168.00 |

1003540493

16. Subsequent to the meeting, of the renewal contract proposals recommended for approval and referred to in paragraph 10, the Scientific Director determined that the following should be funded in the respective amounts indicated:

| | | |
|---|---|---|
| 14-B | Microbiological Associates Inc. | $480,000.00 |
| 15-B | Union Carbide Corporation | $260,000.00 |
| 20-A | Microbiological Associates Inc. | $25,000.00 (Reference c'ette. storage.) |
| 16-B | Scripps Clinic & Research Foundation (Richard A. Lerner, M.D.) | $65,872.00 |
| 22-A | Microbiological Associates Inc. | $900,000.00 |
| 28 | Microbiological Associates Inc. | $40,685.00 (Kouri collaboration with Jay A. Levy, M.D., [grant 1011].) |

17. Subsequent to the meeting, of the deferred applications referred to in paragraph 5, the Scientific Director determined that the following should be funded in the respective amounts indicated:

| | | |
|---|---|---|
| 787-C | Gary Friedman, M.D. | $49,720.00 5/1-10/31/75 |
| 1011 | Jay A. Levy, M.D. | $60,245.00 |

Source: https://www.industrydocuments.ucsf.edu/docs/ykpl0000

18. Subsequent to the meeting, of the deferred applications referred to in paragraph 5, the Scientific Director determined that the following should not be funded:

| | | |
|---|---|---|
| 1010M | Carl G. Becker, M.D. | $29,808.00 |

19. Subsequent to the meeting, of the new applications recommended for approval and referred to in paragraph 7, the Scientific Director determined that the following should not be funded:

| | | |
|---|---|---|
| 864-C | Theodore A. Slotkin, Ph.D. | $18,359.00 |
| 869-A | Ronald P. Rubin, Ph.D. | $18,975.00 |
| 1022 | John L. Egle, Ph.D. | $29,813.00 |
| 1023 | Patricia I. Bader, M.D. | $52,385.00 |

20. Subsequent to the meeting, of the new applications that were deferred to in paragraph 9, the Scientific Director determined that the following should be prorated until the September SAB meeting in the respective amounts indicated:

| | | | |
|---|---|---|---|
| 310-A | Richard J. Bing, M.D. | $11,323.25 | 7/1-9/30/75 |
| 758-C | Hans Meier, D.V.M. | $6,100.25 | 7/1-9/30/75 |

10035404 94

Source: https://www.industrydocuments.ucsf.edu/docs/ykpl0000